Pharmaceutical

Agios sells vorasidenib US royalties for $905m

Royalty Pharma will receive 15% on US sales of vorasidenib, up to $1bn, and at a 12% rate beyond that.

May 31, 2024 - 04:00
Agios sells vorasidenib US royalties for $905m
Royalty Pharma will receive 15% on US sales of vorasidenib, up to $1bn, and at a 12% rate beyond that.
Read the original article

Tags:

Previous Article

Sanofi completes the $1.7bn acquisition of Inhibrx

Next Article

Gilead urged to improve access to HIV drug by public figures and celebrities

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Imugene licenses potential first-to-market allogeneic CAR T for blood cancers

Imugene licenses potential first-to-market allogeneic C...

Aug 18, 2023

Launching pharmaceuticals in Belgium, the Netherlands, and Luxembourg: Opportunities and challenges

Launching pharmaceuticals in Belgium, the Netherlands, ...

Sep 21, 2023

UK takes measures to tackle Utrogestan hormone replacement shortage

UK takes measures to tackle Utrogestan hormone replacem...

May 22, 2023